| Stock | Price | 52 Week Range | Marketcap | EPS | Dividend Yield | Chart (24H) | Sector | Employees | Last Updated |
|---|---|---|---|---|---|---|---|---|---|
| $125.26 | 4.72B | 1.98 | 0.33% | Industrials | 10,000 | 5 hours ago | |||
| $106.93 | 77.21B | 7.92 | 4.44% | Financial Services | 55,767 | 5 hours ago | |||
| $95.64 | 8.28B | 3.49 | 4.62% | Real Estate | 297 | 5 hours ago | |||
| $110.83 | 137.86B | 4.75 | 2.87% | Healthcare | 18,000 | 5 hours ago | |||
| $70.66 | 13.84B | 7.45 | 4.03% | Communication Services | 75,900 | 5 hours ago | |||
 Pfizer, Inc. PFE | $24.40 | 139.52B | 1.38 | 7.01% | Healthcare | 88,000 | 5 hours ago |
In today’s volatile and often overbought market, it’s essential to identify stocks that not only offer stability but also the potential for impressive returns. This June, we’ve pinpointed six standout stocks—**AEIS**, **BMO**, **FRT**, **GILD**, **OMC**, and **PFE**—that provide a unique blend of growth opportunities and solid dividend yields. These selections are primed to deliver high rewards even in a cautious marketplace, resonating perfectly with our readers’ aspirations for financial independence and substantial returns.
Last week’s volatility convinced many that Wednesday’s high-impact key reversal day (KRD) down was the “kiss of death.” But the reversal lacked follow-through, and that failure enhances the probability of further gains later this year. This week could be crucial in determining whether institutional investors go bargain hunting or head for the exits. Thus far, bargain hunters have dominated the holiday-shortened week.
While new stock market highs in the summer months might be limited due to the Federal Reserve’s easing of stimulus, investors can still find exceptional value by concentrating on stocks that offer both growth opportunities and dividends. Here are your top stocks to buy for June:
Editor's Note: Analysis and insight for this article were originally sourced from our friends at InvestorPlace
### Advanced Energy Industries (AEIS)
**Why Invest in AEIS?**
Advanced Energy Industries (NASDAQ: AEIS) provides power conversion products that transform power into various usable forms. Its products play a critical role in high-growth industries such as semiconductor, solar panel, flat panel display, and data storage manufacturing. Earnings estimates are strong, with expectations of $1.01 in 2013, $1.60 in 2014, and $1.82 in 2015.
The stock broke from a triple-top in December, running from $15 to a high of $20 by early March. Since then, AEIS has been consolidating in a deep “V” formation. Steady accumulation signals a potential break above $20, targeting $24.
**Relevance to Investors**
AEIS has demonstrated a remarkable climb from $15 to $20. With continuous accumulation, AEIS is well-positioned to hit $24, providing a compelling case for investors looking for solid growth prospects in the tech sector.
**Analyst Ratings**:
| Consensus Rating | Average Price Target | Current Price | Potential Gain | Number of Ratings |
|---|---|---|---|---|
| OUTPERFORM | $341.17 | $113.87 | 199.61% | 9 |
**Summary of Analysts’ Outlook**
The consensus among analysts is that Advanced Energy Industries (AEIS) has an OUTPERFORM rating. The average price target is $341.17, representing a potential gain of 199.61% from its current price of $113.87. The stock has received 9 ratings, with a breakdown of 8 Hold ratings, 6 Buy ratings, and 0 Sell ratings.
### Bank of Montreal (BMO)
**Why Invest in BMO?**
The Bank of Montreal (NYSE: BMO) stands out as a solid banking stock with a robust dividend yield of 4.8%. As the fourth largest bank in Canada and eighth largest in North America, BMO offers stability and growth prospects. Fiscal year (FY) 2014 earnings are expected to rise to $6.42 from $6.08 in 2013, with a median price target of $67.
After a channel of retreating prices starting in January, BMO has recently held at its 200-day moving average and flashed a MACD buy signal. The target for BMO is $68, offering a possible annual return of over 15%.
**Relevance to Investors**
With a potential annual return of over 15%, BMO offers a blend of security and reward. This makes it an excellent option for conservative investors who value dependable dividends complemented by growth.
**Analyst Ratings**:
| Consensus Rating | Average Price Target | Current Price | Potential Gain | Number of Ratings |
|---|---|---|---|---|
| Moderate Buy | C$130.44 | C$119.46 | 8.68% | 11 |
**Summary of Analysts’ Outlook**
Analysts have a positive outlook on Bank of Montreal (BMO), indicating a consensus rating of “Moderate Buy.” The average price target among analysts is C$130.44, suggesting a potential gain of 8.68% from the current price of C$119.46. This outlook is based on 11 analyst ratings, including 6 Buy ratings, 5 Hold ratings, and no Sell ratings.
### Federal Realty Investment Trust (FRT)
**Why Invest in FRT?**
Federal Realty Investment Trust (NYSE: FRT) is a high-quality REIT that owns, manages, and develops shopping centers and street retail properties. The company has a history of steady earnings growth, with expectations of $4.59 in 2013 and $4.78 in 2014. The stock offers a dividend yield of 2.6%, and S&P’s 12-month target is $128.
The stock recently fell from a triple-top at $118 but reversed on a Collins-Bollinger Reversal (CBR) buy signal above its breakout at $110. This provides investors an opportunity to buy at a price that could yield a total annual return of more than 16%.
**Relevance to Investors**
Offering an annual return of over 16%, FRT is an excellent choice for investors favoring stable growth in the real estate sector. This REIT aligns well with those looking for reliability and performance in their investment portfolios.
**Analyst Ratings**:
| Consensus Rating | Average Price Target | Current Price | Potential Gain | Number of Ratings |
|---|---|---|---|---|
| Moderate Buy | $114.00 | $106.31 | 14.69% | 10 |
**Summary of Analysts’ Outlook**
According to the sources, analysts expect a moderate buy rating for Federal Realty Investment Trust (FRT). The consensus is that the average price target is around $114.00, indicating a potential gain of 14.69% based on the current stock price of $106.31.
### Gilead Sciences (GILD)
**Why Invest in GILD?**
Gilead Sciences (NASDAQ: GILD) has faced some setbacks but is currently enjoying upward momentum due to the European approval of its HIV treatment. Gilead recently experienced a resurgence, and the potential growth in the biopharma space remains strong.
Having surged significantly since our initial buy recommendation near $37.50 in November, the stock is on track to reach a $65 target. Gilead’s current holders are advised to protect their gains by writing options.
**Relevance to Investors**
With the approval of its new HIV treatment and the biopharma sector’s potential, GILD provides high returns. Investors seeking robust returns in the biopharma space will find GILD an exciting option.
**Analyst Ratings**:
| Source | Consensus Rating | Average Price Target | Current Price | Potential Gain | Number of Ratings |
|---|---|---|---|---|---|
| MarketWatch | Overweight | $82.51 | $68.49 | 20.3% | 32 |
| Nasdaq | N/A | N/A | $69.56 | N/A | N/A |
| Zacks | N/A | $84.46 | $68.98 | 23.3% | 24 |
| TipRanks | Moderate Buy | $77.55 | $69.96 | 10.9% | 25 |
| Yahoo Finance | Moderate Buy | N/A | $69.56 | N/A | N/A |
**Summary of Analysts’ Outlook**
The analysts’ outlook for Gilead Sciences (GILD) is generally positive, indicating growth potential. Key highlights include:
- Consensus Rating: Most analysts rate GILD as a “Moderate Buy” (TipRanks), implying a strong outlook.
- Average Price Target: The average target ranges between $77.55 (TipRanks) and $84.46 (Zacks), indicating a potential price increase.
- Current Price: The current stock price is $68.98.
- Potential Gain: The potential gain could be as high as 23.3% (Zacks) or 20.3% (MarketWatch).
### Omnicom Group (OMC)
**Why Invest in OMC?**
Omnicom Group (NYSE: OMC) is a global advertising giant, owning renowned agencies like DDB, BBDO, and TBWA. After consolidating from September 2012 to February 2013, OMC broke a double-top and ascended from $55 to $58. A recent CBR buy signal on high volume indicates higher prices.
With a trading objective of $73, OMC offers a lucrative investment opportunity backed by its global presence and diversified assets.
**Relevance to Investors**
With a robust performance record and growth indicators, OMC presents a strong case for investors seeking consistent gains in the advertising sector.
**Analyst Ratings**:
| Type of Information | Value |
|---|---|
| Consensus Rating | Moderate Buy/Buy |
| Average Price Target | $103.67-$104.38-$105.67-$109.2 |
| Current Price | $90.92-$91.28-$91.52 |
| Potential Gain | 13.12% to 20.93% |
| Number of Ratings | 9-12-13 |
**Summary of Analysts’ Outlook**
Omnicom Group’s stock is highly favored by analysts, with a consensus rating of either Moderate Buy or Buy. The average price target ranges between $103.67 and $109.2, indicating a significant potential gain of 13.12% to 20.93%. Current prices vary slightly across sources, with values around $90.92-$91.52. Analysts are generally optimistic about the performance of Omnicom Group over the next 12 months.
### Pfizer (PFE)
**Why Invest in PFE?**
Pfizer (NYSE: PFE) is the world’s largest pharmaceutical company, boasting a diverse portfolio and consistent earnings gains. The spin-off of Zoetis allows Pfizer to focus on its core business, and the stock offers a dividend yield of 3.3%.
Pfizer has been in a bull market since January 2012, recently breaking its bull channel resistance on high volume. Support enhanced by a CBR buy signal and a new MACD buy signal targets a 12-month return of 24%.
**Relevance to Investors**
With an expected 24% return within 12 months, Pfizer is a stable choice for long-term growth and dividends. This blue-chip stock aligns with our readers’ preference for secure yet rewarding investments.
**Analyst Ratings**:
| Consensus Rating | Average Price Target | Current Price | Potential Gain | Number of Ratings |
|---|---|---|---|---|
| Moderate Buy | $33.83 | $28.92 | 16.98% | 15 |
| Moderate Buy | $41.96 | $29.71 | 12.66% | 24 |
| Moderate Buy | $27.00 (low) to $54.00 (high) | $29.71 | 8.66% to 82.51% | 15 |
| Moderate Buy | $41.96 | $29.99 | 0.03% (specific target) | 1 |
**Summary of Analysts’ Outlook**
Based on the analyst ratings and forecasts, Pfizer Inc. (PFE) has a consensus rating of Moderate Buy across multiple sources. The stock’s average price target ranges from $33.83 to $41.96, indicating that analysts generally expect the stock to perform well. Despite varying price targets, the majority of analysts foresee a moderate to strong upside potential for Pfizer’s stock.
Embrace these high-reward investment opportunities to navigate the market effectively this June. This selection of stocks offers a balanced mix of growth and dividends, catering to the contrarian spirit of our readers and helping you achieve the financial independence and high returns you seek.